MX2009009131A - Mejoras en y con relacion a composiciones medicinales. - Google Patents

Mejoras en y con relacion a composiciones medicinales.

Info

Publication number
MX2009009131A
MX2009009131A MX2009009131A MX2009009131A MX2009009131A MX 2009009131 A MX2009009131 A MX 2009009131A MX 2009009131 A MX2009009131 A MX 2009009131A MX 2009009131 A MX2009009131 A MX 2009009131A MX 2009009131 A MX2009009131 A MX 2009009131A
Authority
MX
Mexico
Prior art keywords
naloxone
buprenorphine
relating
composition
dosage form
Prior art date
Application number
MX2009009131A
Other languages
English (en)
Inventor
Christopher Bourne Chapleo
Neil Hyde
Original Assignee
Reckitt Benckiser Healthcare
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Reckitt Benckiser Healthcare filed Critical Reckitt Benckiser Healthcare
Publication of MX2009009131A publication Critical patent/MX2009009131A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nutrition Science (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Physiology (AREA)
  • Addiction (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Una composición, en forma de dosificación de unidad parenteral o en una forma de dosificación unitaria apropiada para suministrar por medio de la dermis o mucosa, comprende buprenorfina y una cantidad de naloxona de tal manera que la relación en peso de buprenorfina a naloxona suministrada a, o que alcanza el plasma de un paciente está en el intervalo desde 7.5:1 hasta 12.4:1. La acción analgésica de la buprenorfina se potencia por la dosis baja de naloxona, que también sirve para reducir la probabilidad de abuso de la composición por adictos al fármaco. También se proporciona un método para el tratamiento de dolor y el uso de naloxona y buprenorfina para la fabricación de un medicamento.
MX2009009131A 2007-03-01 2008-02-15 Mejoras en y con relacion a composiciones medicinales. MX2009009131A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0703968A GB2447016A (en) 2007-03-01 2007-03-01 Buprenorphine/naloxone compositions
PCT/GB2008/000526 WO2008104738A1 (en) 2007-03-01 2008-02-15 Improvements in and relating to medicinal compositions

Publications (1)

Publication Number Publication Date
MX2009009131A true MX2009009131A (es) 2009-09-03

Family

ID=37965735

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009009131A MX2009009131A (es) 2007-03-01 2008-02-15 Mejoras en y con relacion a composiciones medicinales.

Country Status (17)

Country Link
US (1) US20110046172A1 (es)
EP (1) EP2129380A1 (es)
JP (2) JP2010520186A (es)
KR (1) KR20090117891A (es)
CN (1) CN101626766B (es)
AR (1) AR065579A1 (es)
AU (1) AU2008220574A1 (es)
BR (1) BRPI0807908A2 (es)
CA (1) CA2678582A1 (es)
CL (1) CL2008000606A1 (es)
GB (1) GB2447016A (es)
HK (1) HK1139871A1 (es)
MX (1) MX2009009131A (es)
PE (1) PE20090168A1 (es)
TW (1) TWI451868B (es)
WO (1) WO2008104738A1 (es)
ZA (1) ZA200905664B (es)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5968547A (en) 1997-02-24 1999-10-19 Euro-Celtique, S.A. Method of providing sustained analgesia with buprenorphine
US8765167B2 (en) 2001-10-12 2014-07-01 Monosol Rx, Llc Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions
US8900498B2 (en) 2001-10-12 2014-12-02 Monosol Rx, Llc Process for manufacturing a resulting multi-layer pharmaceutical film
US20190328679A1 (en) 2001-10-12 2019-10-31 Aquestive Therapeutics, Inc. Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions
US8663687B2 (en) 2001-10-12 2014-03-04 Monosol Rx, Llc Film compositions for delivery of actives
US8900497B2 (en) 2001-10-12 2014-12-02 Monosol Rx, Llc Process for making a film having a substantially uniform distribution of components
US10285910B2 (en) 2001-10-12 2019-05-14 Aquestive Therapeutics, Inc. Sublingual and buccal film compositions
US11207805B2 (en) 2001-10-12 2021-12-28 Aquestive Therapeutics, Inc. Process for manufacturing a resulting pharmaceutical film
US20070281003A1 (en) 2001-10-12 2007-12-06 Fuisz Richard C Polymer-Based Films and Drug Delivery Systems Made Therefrom
US8603514B2 (en) 2002-04-11 2013-12-10 Monosol Rx, Llc Uniform films for rapid dissolve dosage form incorporating taste-masking compositions
US20110033542A1 (en) 2009-08-07 2011-02-10 Monosol Rx, Llc Sublingual and buccal film compositions
US7357891B2 (en) 2001-10-12 2008-04-15 Monosol Rx, Llc Process for making an ingestible film
UA102128C2 (en) 2008-12-05 2013-06-10 Х. Луннбек А/С Nalmefene hydrochloride dihydrate
US8475832B2 (en) * 2009-08-07 2013-07-02 Rb Pharmaceuticals Limited Sublingual and buccal film compositions
CA2792878C (en) * 2010-03-12 2019-10-22 Government Of The Usa, As Represented By The Sec., Dept. Of Health And Human Services Agonist/antagonist compositions and methods of use
US8529914B2 (en) * 2010-06-28 2013-09-10 Richard C. Fuisz Bioactive dose having containing a material for modulating pH of a bodily fluid to help or hinder absorption of a bioactive
US9149959B2 (en) 2010-10-22 2015-10-06 Monosol Rx, Llc Manufacturing of small film strips
KR101944367B1 (ko) * 2011-08-18 2019-01-31 바이오딜리버리 사이언시스 인터내셔널 인코포레이티드 부프레노르핀 운반용 약물남용 억제 점막 부착 장치
AU2012311293B2 (en) * 2011-09-19 2014-02-20 Orexo Ab New abuse-resistant pharmaceutical composition for the treatment of opioid dependence
MX362217B (es) * 2011-12-21 2019-01-09 Biodelivery Sciences Int Inc Dispositivos de administracion de farmacos por via transmucosal para uso en el alivio del dolor cronico.
CN103690495B (zh) * 2013-12-19 2015-04-08 贵州景峰注射剂有限公司 注射用盐酸纳洛酮的冷冻干燥方法
SG10202003562WA (en) 2014-03-14 2020-05-28 Opiant Pharmaceuticals Inc Nasal drug products and methods of their use
US9480644B2 (en) 2014-03-14 2016-11-01 Opiant Pharmaceuticals, Inc. Nasal drug products and methods of their use
US10085937B2 (en) 2014-03-14 2018-10-02 Adapt Pharma Limited Nasal drug products and methods of their use
US9561177B2 (en) 2014-03-14 2017-02-07 Adapt Pharma Limited Nasal drug products and methods of their use
KR20230137362A (ko) 2016-05-05 2023-10-04 어퀘스티브 테라퓨틱스, 아이엔씨. 강화된 전달 에프네프린 조성물
US11273131B2 (en) 2016-05-05 2022-03-15 Aquestive Therapeutics, Inc. Pharmaceutical compositions with enhanced permeation

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8332556D0 (en) * 1983-12-06 1984-01-11 Reckitt & Colmann Prod Ltd Analgesic compositions
JPH1036265A (ja) * 1996-07-19 1998-02-10 Nitto Denko Corp ブプレノルフィン経皮吸収製剤
AR031682A1 (es) * 1999-11-19 2003-10-01 Reckitt Benckiser Helthcare Uk Composiciones farmaceuticas
WO2004014336A2 (de) * 2002-08-09 2004-02-19 Grünenthal GmbH Opiod-rezeptor-antagonisten in transdermalen systemen mit buprenorphin
US20050191340A1 (en) * 2002-08-09 2005-09-01 Gruenenthal Gmbh Opioid-receptor antagonists in transdermal systems having buprenorphine

Also Published As

Publication number Publication date
AR065579A1 (es) 2009-06-17
CA2678582A1 (en) 2008-09-04
ZA200905664B (en) 2010-10-27
US20110046172A1 (en) 2011-02-24
GB0703968D0 (en) 2007-04-11
GB2447016A (en) 2008-09-03
EP2129380A1 (en) 2009-12-09
CN101626766B (zh) 2013-07-10
CL2008000606A1 (es) 2008-10-03
KR20090117891A (ko) 2009-11-13
BRPI0807908A2 (pt) 2014-06-17
JP2014196325A (ja) 2014-10-16
TWI451868B (zh) 2014-09-11
TW200843773A (en) 2008-11-16
AU2008220574A1 (en) 2008-09-04
CN101626766A (zh) 2010-01-13
PE20090168A1 (es) 2009-03-19
JP2010520186A (ja) 2010-06-10
WO2008104738A1 (en) 2008-09-04
HK1139871A1 (en) 2010-09-30

Similar Documents

Publication Publication Date Title
HK1139871A1 (en) Improvements in and relating to medicinal compositions
MX2009009132A (es) Composiciones medicinales mejoradas que comprenden buprenorfina y naltrexona.
JP2010520186A5 (es)
JP2010520183A5 (es)
CA2661759A1 (en) Buprenophine-wafer for drug substitution therapy
NZ605887A (en) Pharmaceutical dosage form comprising 6’-fluoro-(n-methyl- or n,n-dimethyl-)-4-phenyl-4’,9’-dihydro-3’h-spiro[cyclohexane-1,1’-pyrano[3,4,b]indol]-4-amine for the treatment of neuropathic pain
MX2009009133A (es) Composiciones medicinales mejoradas que comprenden buprenorfina y naloxona.
MX2011013902A (es) Tratamiento de esclerosis multiple con laquinimod.
EP2708256A3 (en) Device and method for delivery of a medicament
WO2007098479A3 (en) Localized insulin delivery for bone healing
TW200806318A (en) Uses of anti-insulin-like growth factor I receptor antibodies
MX2009009134A (es) Composiciones medicinales mejoradas que comprenden buprenorfina y nalmefeno.
SG169233A1 (en) Pharmaceutical compositions comprising apomorphine for pulmonary inhalation
NZ587202A (en) Methods for measuring a patient response upon administration of a drug and compositions thereof
NZ595467A (en) Sublingual pharmaceutical composition comprising a neutral oil
BRPI0510895A (pt) formulação farmacêutica de 10-propargila-10-deazaaminopterina para tratamento de linfoma de célula t
WO2005055921A3 (en) Compositions for treatment of ear disorders and methods of use thereof
IL196425A (en) Dosage unit for oral administration containing ibuprofen and pamotidine
JP2010520185A5 (es)
NZ591525A (en) Methods of treatment of complicated skin and skin structure infections using single doses of oritavancin
WO2008025790A3 (en) Use of opioid formulations in needle-less drug delivery devices
HRP20192189T1 (hr) Doziranja i terapijske primjene l-4-klorokinurenina
JP2010520184A5 (es)
JP2016505050A5 (es)
MX2013003523A (es) Composicion farmaceutica de dosis baja.

Legal Events

Date Code Title Description
GB Transfer or rights

Owner name: RB PHARMACEUTICALS LIMITED.*

FA Abandonment or withdrawal